Literature DB >> 31062130

Immunohistochemical assessment of growth factor signaling molecules: MAPK, Akt, and STAT3 pathways in oral epithelial precursor lesions and squamous cell carcinoma.

Kazuki Tashiro1, Mariko Oikawa2, Yasuhiro Miki3, Tetsu Takahashi4, Hiroyuki Kumamoto2.   

Abstract

Several growth factors and their receptors, such as epidermal growth factor receptor, have been studied as prognostic biomarkers for many epithelial malignancies. The signal transduction cascade of those receptors includes RAS/RAF/ERK, PI3K/Akt/mTOR, and STAT3 pathways. The aim of this study was to investigate the expression levels of several key proteins of those pathways in patients with oral squamous cell carcinoma (OSCC) and oral epithelial precursor lesions (OEPLs), and to correlate the expressions of these proteins with clinicopathologic features and prognosis. Fifteen leukoplakia (LP), 15 low-grade epithelial dysplasia, 15 high-grade epithelial dysplasia (HD), and 132 OSCC specimens were immunohistochemically examined for KRAS, HRAS, NRAS, BRAF, pERK1/2, pAkt, pmTOR, and pSTAT3 expression. Immunoreactivity for these molecules predominantly occurred in regions OEPL basal to prickle layers and in most OSCC cells. KRAS and NRAS expression was significantly lower in OSCC than in OEPLs, while pAkt and pmTOR showed higher expression in OSCC than in OEPLs. pERK1/2 expression was significantly higher in HD than in LP. In OSCC, KRAS and NRAS immunoreactivity was significantly higher in advanced age and male gender. In addition, higher immunoreactivity was shown in pERK1/2 in female gender and advanced TNM stage, pAkt in advanced T classification and cases without postoperative metastasis, pmTOR in advanced mode of invasion, and pSTAT3 in invasion depth. Correlations between these markers and clinicopathological variables were also noted. MAPK, Akt, and STAT3 pathways might play diverse roles in oral carcinogenesis.

Entities:  

Keywords:  Akt; MAPK; Oral epithelial precursor lesions (OEPLs); Oral squamous cell carcinoma (OSCC); STAT3

Mesh:

Substances:

Year:  2019        PMID: 31062130     DOI: 10.1007/s10266-019-00428-4

Source DB:  PubMed          Journal:  Odontology        ISSN: 1618-1247            Impact factor:   2.634


  38 in total

1.  Stat3 is involved in the motility, metastasis and prognosis in lingual squamous cell carcinoma.

Authors:  Yan Zhao; Jiali Zhang; Haibin Xia; Bi Zhang; Tao Jiang; Jiawei Wang; Xinmin Chen; Yining Wang
Journal:  Cell Biochem Funct       Date:  2012-02-03       Impact factor: 3.685

2.  Expression of aquaporin 8 and phosphorylation of Erk1/2 in cervical epithelial carcinogenesis: correlation with clinicopathological parameters.

Authors:  Heng Chang; Yonghua Shi; Talaf Tuokan; Rui Chen; Xiaoqian Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Prognostic value of activated Akt expression in oral squamous cell carcinoma.

Authors:  J Lim; J-H Kim; J-Y Paeng; M-J Kim; S-D Hong; J-I Lee; S-P Hong
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

4.  Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.

Authors:  Hye Sung Won; Chan-Kwon Jung; Sang Hoon Chun; Jin-Hyoung Kang; Yeon-Sil Kim; Dong-Il Sun; Min-Sik Kim
Journal:  Oral Oncol       Date:  2012-06-08       Impact factor: 5.337

5.  Long-term treatment outcome of oral premalignant lesions.

Authors:  P Holmstrup; P Vedtofte; J Reibel; K Stoltze
Journal:  Oral Oncol       Date:  2005-11-28       Impact factor: 5.337

6.  Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma.

Authors:  Monique M Nijkamp; Ilse J Hoogsteen; Paul N Span; Robert P Takes; Jasper Lok; Paul F Rijken; Albert J van der Kogel; Johan Bussink; Johannes H A M Kaanders
Journal:  Radiother Oncol       Date:  2011-07-19       Impact factor: 6.280

7.  Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis.

Authors:  Seon Young Nam; Hye Seung Lee; Gyung-Ah Jung; Jimi Choi; Sung Jin Cho; Min Kyu Kim; Woo Ho Kim; Byung Lan Lee
Journal:  APMIS       Date:  2003-12       Impact factor: 3.205

8.  Mutations of the BRAF gene in squamous cell carcinoma of the head and neck.

Authors:  Anette Weber; Larissa Langhanki; Florian Sommerer; Annett Markwarth; Christian Wittekind; Andrea Tannapfel
Journal:  Oncogene       Date:  2003-07-24       Impact factor: 9.867

Review 9.  Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling.

Authors:  Jacques Pouysségur; Véronique Volmat; Philippe Lenormand
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

10.  TWIST and p-Akt immunoexpression in normal oral epithelium, oral dysplasia and in oral squamous cell carcinoma.

Authors:  Bruno-Santos de Freitas Silva; Fernanda-Paula Yamamoto; Flávia-Sirotheau Corrêa Pontes; Sérgio Elias-Vieira Cury; Felipe-Paiva Fonseca; Hélder Antonio-Rebelo Pontes; Décio-dos Santos Pinto-Júnior
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-01-01
View more
  8 in total

Review 1.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

Review 2.  Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.

Authors:  Choudhary Harsha; Kishore Banik; Hui Li Ang; Sosmitha Girisa; Rajesh Vikkurthi; Dey Parama; Varsha Rana; Bano Shabnam; Elina Khatoon; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

3.  Azoxystrobin induces apoptosis via PI3K/AKT and MAPK signal pathways in oral leukoplakia progression.

Authors:  Lingyu Li; Jing Li; Hui Chen; Yajun Shen; Yunping Lu; Min Zhang; Xiaofei Tang
Journal:  Front Pharmacol       Date:  2022-08-04       Impact factor: 5.988

Review 4.  STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma.

Authors:  Mingjing Jiang; Bo Li
Journal:  Cells       Date:  2022-10-05       Impact factor: 7.666

5.  Recurrence in Oral Premalignancy: Clinicopathologic and Immunohistochemical Analysis.

Authors:  Maria Georgaki; Dimitris Avgoustidis; Vasileios Ionas Theofilou; Evangelia Piperi; Efstathios Pettas; Demos G Kalyvas; Dimitrios Vlachodimitropoulos; Christos Perisanidis; Andreas C Lazaris; Nikolaos G Nikitakis
Journal:  Diagnostics (Basel)       Date:  2021-05-12

6.  Bupivacaine inhibits the malignant biological behavior of oral squamous cell carcinoma cells by inhibiting the activation of ERK1/2 and STAT3.

Authors:  Zhongchao Wang; Jie Zhang; Yongmei Wen; Pin Wang; Liyuan Fan
Journal:  Ann Transl Med       Date:  2021-05

7.  Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution.

Authors:  Ying-Xue Li; Shan-Shan Ding; Wen-Juan Wen; Lin Han; Hong-Qun Wang; Huai-Yin Shi
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

8.  Antitumor Activity of the Cardiac Glycoside αlDiginoside by Modulating Mcl-1 in Human Oral Squamous Cell Carcinoma Cells.

Authors:  Jing-Ru Weng; Wei-Yu Lin; Li-Yuan Bai; Jing-Lan Hu; Chia-Hsien Feng
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.